Meeting
2023 ASCO Annual Meeting
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.
Authors
Chiara Molinelli
Università degli Studi di Genova, Genoa, Italy
Chiara Molinelli , Flavia Jacobs , Elisa Agostinetto , Guilherme Nader Marta , Marcello Ceppi , Marco Bruzzone , Eva Blondeaux , Francesco Schettini , Aleix Prat , Giuseppe Viale , Lucia Del Mastro , Matteo Lambertini , Evandro de Azambuja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1104)
DOI
10.1200/JCO.2023.41.16_suppl.1104
Abstract #
1104
Poster Bd #
325
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.
First Author: Paul Stewart
Poster
2023 ASCO Annual Meeting
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
First Author: Biyun Wang
Poster
2022 ASCO Annual Meeting
Delayed versus immediate start of chemotherapy in asymptomatic patients with metastatic cancer: A systematic review and meta-analysis.
First Author: Simone Augustinus
Poster
2022 ASCO Annual Meeting
Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers.
First Author: Pascal Pujol